Altamira Therapeutics Stock Price, News & Analysis

Altamira Therapeutics Ltd (CYTOF) is a biotechnology company focused on peptide-based nanoparticle technologies for efficient delivery of nucleic acids and RNA therapeutics. According to company disclosures, Altamira is dedicated to developing and supplying its xPhore™ platform to partners in the biotech and pharmaceutical industries for use in their own drug development programs. The company is classified in the healthcare sector and biotechnology industry and trades on the OTCQB market under the symbol CYTOF.

Altamira states that its core technology, the xPhore™ platform, is designed for extrahepatic delivery, meaning delivery to tissues and organs beyond the liver. The platform uses a patented peptide-based nanoparticle approach that can engage different nucleic acid modalities and assemble them into nanoparticles. The company reports that xPhore is suited for siRNA, mRNA, circular RNA (circRNA), and DNA, and that it protects payloads from degradation, supports cellular uptake, and enables pH-dependent endosomal escape and cytoplasmic delivery.

Business Model and Platform Offerings

Altamira describes its RNA and nucleic acid delivery activities as a licensing-focused, “picks and shovels” strategy. Rather than developing a broad pipeline of proprietary therapeutics alone, the company aims to out-license its delivery technologies to other biotech and pharma companies. Under this model, partners evaluate the feasibility and efficacy of their own RNA or DNA payloads delivered via xPhore-based nanoparticles, with the potential to negotiate licensing agreements if results are positive.

The xPhore platform is adapted into several branded sub-platforms for specific nucleic acid types, as described in company communications:

• OligoPhore™ – for oligonucleotides and short RNA payloads (siRNA and related modalities).
• SemaPhore™ – for linear mRNA, including applications such as mRNA vaccines and other mRNA-based therapeutics.
• CycloPhore™ – for circular RNA (circRNA), which the company notes is an emerging modality with potential for enhanced protein expression and greater stability compared to linear mRNA.
• GenePhore™ – for DNA delivery, including plasmid DNA, offered as an extension of xPhore after in vitro experiments demonstrated efficient transfection and protein expression.

Altamira reports that it collaborates with partners to test these platforms in vitro and in vivo. For example, the company has disclosed collaborations involving SemaPhore for mRNA vaccine delivery and CycloPhore for circular RNA payloads, as well as feasibility work with DNA delivery under the GenePhore label. These collaborations may lead to licensing discussions if evaluation results support further development.

Flagship Internal Programs

In addition to partnering activities, Altamira maintains two proprietary flagship siRNA programs that use its xPhore delivery technology:

• AM-401 – an siRNA-based program targeting KRAS-driven cancer. The company states that AM-401 is in preclinical development beyond in vivo proof of concept.
• AM-411 – an siRNA-based program for rheumatoid arthritis, also described as being in preclinical development beyond in vivo proof of concept.

These programs illustrate how Altamira applies its own delivery platform to disease areas characterized by inflammation and oncogenic signaling, while also using the same technology base for external collaborations.

Legacy Assets and Associate Company

Alongside its RNA and nucleic acid delivery focus, Altamira refers to several “legacy assets” that are considered non-core to its current strategic direction. A key element is its 49% stake (with additional economic rights) in Altamira Medica AG (“Medica”), an associate company. Medica owns and commercializes Bentrio®, which Altamira describes as its commercial-stage legacy asset.

Bentrio is characterized as an over-the-counter, drug-free, preservative-free nasal spray for the treatment or prevention of allergic rhinitis and, where approved, for protection against airborne viruses. Company communications explain that upon intranasal application, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to reduce contact between airborne particles and nasal cells, bind allergens or other particles, and support their discharge. Altamira reports that Bentrio’s efficacy and safety have been evaluated in four clinical trials, including the NASAR study in seasonal allergic rhinitis, and that Bentrio has shown statistically significant improvements in nasal symptoms and health-related quality of life compared with saline spray, with a safety profile similar to saline.

Altamira notes that Bentrio is commercialized through a network of marketing and distribution partners. The company has highlighted milestones such as certification under the European Union Medical Device Regulation (MDR), enabling commercialization in EU member states, and marketing approval in Mainland China for allergic rhinitis, where Medica’s partner Nuance Pharma is responsible for marketing and distribution. The company also reports that Bentrio has been cleared by the U.S. Food and Drug Administration and that it is working with partners to expand its presence in various regions.

Beyond Bentrio, Altamira lists additional legacy programs that it is seeking to partner or divest:

• AM-125 – an intranasal formulation of betahistine developed for acute vestibular syndrome (AVS) and potentially other central nervous system disorders. The company notes that AM-125 is designed to circumvent first-pass metabolism and has demonstrated higher bioavailability than oral betahistine. Altamira reports broad patent coverage for AM-125, including an allowable patent application in Japan and coverage in more than 50 countries worldwide.
• AM-111 – described as a cell-penetrating peptide for the treatment of acute hearing loss, with orphan drug designation and Phase 3 clinical development status.
• AM-102 – an oral small molecule in preclinical development for the treatment of tinnitus.

Altamira has indicated that it is in the process of partnering or divesting these inner ear and related legacy assets while concentrating resources on its RNA and nucleic acid delivery platform.

Corporate Structure, Location, and Operations

Altamira Therapeutics was founded in 2003. The company states that it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. Its RNA delivery business is operated through its Swiss subsidiary Altamira Therapeutics AG (ATAG). Altamira has reported that it is working on a partial spin-off of ATAG to private equity investors, with the goal of funding and expanding the RNA delivery business through a separate capital structure while retaining a significant interest.

The company has also disclosed that part of its research and development team operates from facilities in the Switzerland Innovation Park near Basel, where it has access to laboratory infrastructure supporting nanoparticle formulation, analytical method development, and process development for manufacturing.

Research, Development, and Collaborations

Altamira’s public communications emphasize ongoing work to refine and industrialize its xPhore platform. The company reports efforts in:

• Nanoparticle formulation development.
• Process development for nanoparticle manufacturing.
• Analytical method development and reproducibility of manufacturing.
• Stability testing of nanoparticles.

In its collaboration activities, Altamira has disclosed multiple projects where partners evaluate xPhore-based delivery for their own payloads. Examples include:

• Evaluation of SemaPhore for mRNA vaccine delivery with a partner, with the goal of potentially enabling lower mRNA doses and more efficient vaccines.
• Use of SemaPhore nanoparticles in conjunction with a partner’s proprietary radiopharmaceutical for cancer treatment, tested in vitro and in vivo.
• Collaboration on CycloPhore for delivery of circular RNA payloads under development by an undisclosed partner, with an option to negotiate a license agreement under certain conditions.
• Testing of xPhore for DNA delivery, leading to the GenePhore offering for DNA-based applications such as DNA vaccines, gene editing, or protein replacement therapies, as described by the company.

Through these activities, Altamira positions itself as a technology provider in the RNA and nucleic acid therapeutics ecosystem, with revenues expected to be driven primarily by licensing and collaboration agreements rather than by direct commercialization of multiple finished drugs.

Stock and Investor Context

Altamira Therapeutics’ shares trade on the OTCQB market under the ticker CYTOF. The company has communicated business updates and financial results through press releases, including details on operating loss, research and development spending, and general and administrative expenses. It has also highlighted plans to reduce operating expenses over time, in part through the planned partial spin-off of its RNA delivery subsidiary and through partnering or divestiture of legacy assets.

Investors researching CYTOF can use this overview to understand that Altamira is a biotechnology platform company centered on RNA and nucleic acid delivery technology, with additional exposure to commercial and late-stage assets in allergy, vestibular disorders, and inner ear indications through its legacy portfolio and associate company.

Key Points Summary

• Biotechnology company in the healthcare sector, trading as CYTOF on OTCQB.
• Core focus on peptide-based nanoparticle delivery (xPhore™) for siRNA, mRNA, circRNA, and DNA.
• Business model based on out-licensing and collaborations with biotech and pharma partners.
• Two internal flagship siRNA programs: AM-401 (KRAS-driven cancer) and AM-411 (rheumatoid arthritis), both in preclinical development beyond in vivo proof of concept.
• 49% stake in Altamira Medica AG, which owns Bentrio®, an OTC nasal spray for allergic rhinitis, with MDR certification in the EU and marketing approval in Mainland China.
• Legacy inner ear and CNS-related assets (AM-125, AM-111, AM-102) targeted for partnering or divestiture.
• Founded in 2003, headquartered in Hamilton, Bermuda, with main operations in Basel, Switzerland.